Exelixis
EXEL
$23.70
Share price
0.72%
Change (1 day)
29.51%
Change (1 year)
Categories
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.
Exelixis (EXEL) - Net assets
Net assets on the balance sheet as of December 2023 : $2.26 B
According to Exelixis's latest financial reports the company has $2.26 B in net assets.
A company’s net assets is the sum of its assets minus the sum of its liabilities.
Exelixis - Net assets on balance sheet (from 2001 to 2023)
Net assets by year
| Year | Net assets | Change |
|---|---|---|
| 2023-12-31 | $2.26 B | -9.02% |
| 2022-12-31 | $2.48 B | 12.57% |
| 2021-12-31 | $2.21 B | 17.64% |
| 2020-12-31 | $1.87 B | 11.46% |
| 2019-12-31 | $1.68 B | 30.95% |
| 2018-12-31 | $1.28 B | 351.8% |
| 2017-12-31 | $0.28 B | 219.04% |
| 2016-12-31 | $89.31 M | -163.43% |
| 2015-12-31 | $-0.15 B | 22.62% |
| 2014-12-31 | $-0.12 B | -273.36% |
| 2013-12-31 | $66.23 M | -77.66% |
| 2012-12-31 | $0.29 B | 227.07% |
| 2011-12-31 | $90.63 M | -139.69% |
| 2010-12-31 | $-0.23 B | 39.46% |
| 2009-12-31 | $-0.17 B | 191.01% |
| 2008-12-31 | $-56.27 M | -165.79% |
| 2007-12-31 | $85.51 M | -5.63% |
| 2006-12-31 | $90.61 M | 58.15% |
| 2005-12-31 | $57.29 M | 13.07% |
| 2004-12-31 | $50.67 M | -68.62% |
| 2003-12-31 | $0.16 B | -8.21% |
| 2002-12-31 | $0.17 B | -25.84% |
| 2001-12-31 | $0.23 B |
Net assets for similar companies or competitors
| Company | Net assets | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $68.77 B | 2,937.84% | 🇺🇸 USA |
 Pfizer PFE | $89.28 B | 3,843.97% | 🇺🇸 USA |
 Amgen AMGN | $6.23 B | 175.28% | 🇺🇸 USA |
 Sanofi SNY | $82.20 B | 3,531.04% | 🇫🇷 France |
 Merck MRK | $37.63 B | 1,562.39% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $16.54 B | 630.95% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $16.28 B | 619.46% | 🇬🇧 UK |
 Curis CRIS | $19.67 M | -99.13% | 🇺🇸 USA |
 AVEO Oncology
AVEO | $28.84 M | -98.73% | 🇺🇸 USA |